257 related articles for article (PubMed ID: 18290873)
1. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K; Watson A; Soro-Paavonen A
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
[TBL] [Abstract][Full Text] [Related]
2. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
Ramasamy R; Yan SF; Schmidt AM
Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
[TBL] [Abstract][Full Text] [Related]
3. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
Yonekura H; Yamamoto Y; Sakurai S; Petrova RG; Abedin MJ; Li H; Yasui K; Takeuchi M; Makita Z; Takasawa S; Okamoto H; Watanabe T; Yamamoto H
Biochem J; 2003 Mar; 370(Pt 3):1097-109. PubMed ID: 12495433
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
[TBL] [Abstract][Full Text] [Related]
6. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2007; 68(5):1096-8. PubMed ID: 17097822
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
Rojas A; Morales MA
Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
[TBL] [Abstract][Full Text] [Related]
8. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.
Jensen LJ; Østergaard J; Flyvbjerg A
Horm Metab Res; 2005 Apr; 37 Suppl 1():26-34. PubMed ID: 15918107
[TBL] [Abstract][Full Text] [Related]
9. The RAGE axis in early diabetic retinopathy.
Barile GR; Pachydaki SI; Tari SR; Lee SE; Donmoyer CM; Ma W; Rong LL; Buciarelli LG; Wendt T; Hörig H; Hudson BI; Qu W; Weinberg AD; Yan SF; Schmidt AM
Invest Ophthalmol Vis Sci; 2005 Aug; 46(8):2916-24. PubMed ID: 16043866
[TBL] [Abstract][Full Text] [Related]
10. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
11. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
12. The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats.
Renard C; Chappey O; Wautier MP; Nagashima M; Morser J; Scherrmann JM; Wautier JL
J Pharmacol Exp Ther; 1999 Sep; 290(3):1458-66. PubMed ID: 10454525
[TBL] [Abstract][Full Text] [Related]
13. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
Park L; Raman KG; Lee KJ; Lu Y; Ferran LJ; Chow WS; Stern D; Schmidt AM
Nat Med; 1998 Sep; 4(9):1025-31. PubMed ID: 9734395
[TBL] [Abstract][Full Text] [Related]
14. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
Yan SF; Ramasamy R; Naka Y; Schmidt AM
Circ Res; 2003 Dec; 93(12):1159-69. PubMed ID: 14670831
[TBL] [Abstract][Full Text] [Related]
15. Expression of receptors for advanced glycosylated end-products in renal disease.
Abel M; Ritthaler U; Zhang Y; Deng Y; Schmidt AM; Greten J; Sernau T; Wahl P; Andrassy K; Ritz E
Nephrol Dial Transplant; 1995; 10(9):1662-7. PubMed ID: 8559486
[TBL] [Abstract][Full Text] [Related]
16. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes.
Shoji T; Koyama H; Morioka T; Tanaka S; Kizu A; Motoyama K; Mori K; Fukumoto S; Shioi A; Shimogaito N; Takeuchi M; Yamamoto Y; Yonekura H; Yamamoto H; Nishizawa Y
Diabetes; 2006 Aug; 55(8):2245-55. PubMed ID: 16873687
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
18. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs).
Collison KS; Parhar RS; Saleh SS; Meyer BF; Kwaasi AA; Hammami MM; Schmidt AM; Stern DM; Al-Mohanna FA
J Leukoc Biol; 2002 Mar; 71(3):433-44. PubMed ID: 11867681
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A; Beckman JA; Schmidt AM; Creager MA
Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
[TBL] [Abstract][Full Text] [Related]
20. Blood cells and vascular cell interactions in diabetes.
Wautier JL; Wautier MP
Clin Hemorheol Microcirc; 2001; 25(2):49-53. PubMed ID: 11790870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
